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A B S T R A C T
Background
Febrile neutropenia (FN) and other infectious complications are some of the most serious treatment-related toxicities of chemotherapy
for cancer, with a mortality rate of 2% to 21%. The two main types of prophylactic regimens are granulocyte (G-CSF) or granulocyte-
macrophage colony stimulating factors (GM-CSF); and antibiotics, frequently quinolones or cotrimoxazole. Important current guide-
lines recommend the use of colony stimulating factors when the risk of febrile neutropenia is above 20% but they do not mention
the use of antibiotics. However, both regimens have been shown to reduce the incidence of infections. Since no systematic review has
compared the two regimens, a systematic review was undertaken.
Objectives
To compare the effectiveness of G-CSF or GM-CSF with antibiotics in cancer patients receiving myeloablative chemotherapy with
respect to preventing fever, febrile neutropenia, infection, infection-related mortality, early mortality and improving quality of life.
Search strategy
We searched The Cochrane Library, MEDLINE, EMBASE, databases of ongoing trials, and conference proceedings of the American
Society of Clinical Oncology and the American Society of Hematology (1980 to 2007). We planned to include both full-text and
abstract publications.
Selection criteria
Randomised controlled trials comparing prophylaxis with G-CSF or GM-CSF versus antibiotics in cancer patients of all ages receiving
chemotherapy or bone marrow or stem cell transplantation were included for review. Both study arms had to receive identical chemo-
therapy regimes and other supportive care.
Data collection and analysis
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Trial eligibility and quality assessment, data extraction and analysis were done in duplicate. Authors were contacted to obtain missing
data.
Main results
We included two eligible randomised controlled trials with 195 patients. Due to differences in the outcomes reported, the trials
could not be pooled for meta-analysis. Both trials showed non-significant results favouring antibiotics for the prevention of fever or
hospitalisation for febrile neutropenia.
Authors’ conclusions
There is no evidence for or against antibiotics compared to G(M)-CSFs for the prevention of infections in cancer patients.
P L A I N L A N G U A G E S U M M A R Y
Prophylactic antibiotics or G-CSF for the prevention of infections and improvement of survival in cancer patients undergoing
chemotherapy
Cancer treatment with chemotherapy (anti-cancer drugs) or bone marrow or stem cell transplantation disrupts the immune system
and lowers white blood cell counts. This increases a person’s risk of infection. Both granulocyte colony stimulating factors (GSF) and
antibiotics can reduce the risk of infection associated with cancer treatments. The review compared the effectiveness of antibiotics to
GSFs for the prevention of infection and death. Only two studies were found that compared the two methods of prophylaxis. The
studies could not be pooled but both showed a non-significant trend towards a reduction of infection or fever in patients receiving
antibiotics. More research is needed to determine the best prophylaxis against infection in cancer patients.
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B A C K G R O U N D
Description of the condition
Febrile neutropenia (FN) and other infectious complications are
some of the most serious treatment-related toxicities of chemo-
therapy for cancer. The risk of febrile neutropenia and subse-
quent infection is directly related to the duration and severity of
neutropenia (Bodey 1966; Bodey 1986). Infectious complications
constitute major dose-limiting side effects in patients undergoing
myelosuppressive therapy. Special risk circumstances such as pa-
tient age greater than 65 years or poor performance status impact
on the associated morbidity and mortality (Kuderer 2006; Pizzo
1999). The mortality rate associated with febrile neutropenia in
cancer patients is between 2% to 21% (Smith 2006).
FN can be prevented by a prophylactic regimen. Prophylaxis
started upfront in the first chemotherapy cycle or in parallel with
documented or anticipated neutropenia is called primary prophy-
laxis, whereas secondary prophylaxis is given to patients who had
already experienced episodes of FN in an earlier chemotherapy
cycle. Effective prophylaxis using either colony stimulating factors
or antibiotics (or both) would decrease clinically relevant negative
outcomes such as all cause mortality, infection-related mortality,
and infectious complications. Given the high costs of the conse-
quences of FN, and also of the colony stimulating factors them-
selves, economic arguments are introduced into discussions on the
best prophylactic strategy (Kuderer 2006; Leibovici 2006; Tjan-
Heijnen 2003).
Another alternative, immunglobulins is not effective in preventing
infections in patients with haematological malignancies (Raanani
2008).
In clinical trials addressing the prevention of FN, granulocyte or
granulocyte-macrophage colony stimulating factors (G(M)-CSFs)
have been reported to be effective in reducing the duration and
severity of chemotherapy-induced febrile neutropenia (Johnston
2000; Jones 1996; Holmes 2002). Prophylaxis using antibiotics
has also been shown to be beneficial with reduced fever, incidence
of infections, and hospitalisations (Bucaneve 2005; Cullen 2005)
for example. The prophylactic strategy of combining antibiotics
and G-CSF succeeded in reducing the incidence of FN as well (
Timmer-Bonte 2005).
Description of the intervention
Colony stimulating factors
G(M)-CSF predominantly augments the proliferation, matura-
tion, and release of neutrophils, resulting in a dose-dependent in-
crease in circulating neutrophils (Bronchud 1988;Morstyn 1988).
G-CSF is a growth factor for the myeloid lineage that stimulates
the growth of granulocytes and eosinophil colonies;GM-CSFs also
stimulate the growth of macrophages (Griffin 1990). G-CSF and
GM-CSF are usually well tolerated with only a moderate number
of adverse events. Limited information is available regarding dif-
ferences in the incidence of adverse events between the two types
of colony stimulating factors (Smith 2006). Little information is
also available about the comparative efficacy of these two agents (
Smith 2006). The prophylactic efficacy of colony stimulating fac-
tors is independent of the infectious organism and they are be-
lieved to function via the shortening of the neutropenic episode.
The current ASCO guidelines (Smith 2006) justify the adminis-
tration of CSFs in clinical settings where the expected risk of suf-
fering FN is approximately 20%. In addition to the myelotoxicity
of the planned chemotherapy regimen, patient-specific risk factors
are to be taken into account. Secondary prophylaxis with CSFs
is recommended for patients who have developed a neutropenic
complication in a previous chemotherapy cycle and in whom a
reduced dose might compromise disease-free or overall survival,
or treatment outcome. Other guidelines such as the NCCN and
the EORTC have similar recommendations (Aapro 2006; Lyman
2005).
Thus far, randomised controlled trials (Crawford 1991; Trillet-
Lenoir 1993) and subsequent meta-analyses have shown that pri-
mary prophylaxis with CSF is effective, in both patients with solid
and haematological malignancies, in reducing FN (Bohlius 2008;
Hackshaw 2004; Lyman 2002; Sung 2004; Sung 2007; Wittman
2006). Furthermore, G(M)-CSFs may decrease hospitalisation
and the use of intravenous therapeutic antibiotics (Crawford 1991;
Trillet-Lenoir 1993). In a meta-analysis on the use of G(M)-CSFs
in cancer patients hospitalised with established FN a possible ben-
efit of adding G(M)-CSFs to antibiotic treatment on infection-re-
lated mortality and length of hospitalisation was observed (Clark
2005). Recently a meta-analysis by Kuderer 2006 showed that un-
der certain standard dose chemotherapy regimens early and in-
fection-related mortality were also reduced with primary G-CSF
prophylaxis. However, none of the meta-analyses with less restric-
tive inclusion criteria were able to demonstrate that prophylac-
tic administration of G(M)-CSF improved overall survival when
compared to placebo or no treatment. None of these analyses ad-
dressed the question of G(M)-CSF versus antibiotics, which is
a question closer to clinical reality. One analysis did a subgroup
analysis of those studies in which the published report mandated
antibiotic prophylaxis compared to those that did not and found
no difference between the groups (Sung 2007). This may be due
to the high number of trials where no information about antibi-
otic prophylaxis use is available. In addition, this meta-analysis
included studies that analysed cycles of chemotherapy as opposed
to patients. The distortive effect of such an analysis is difficult to
estimate.
Of the many meta-analyses looking at G(M)-CSF versus placebo
or no treatment only one meta-analysis, restricted to patients with
lymphoma,was published inThe Cochrane Library (Bohlius 2008).
This analysis found a reduction in the rate of infections (odds ra-
tio (OR) 0.74; 95% CI 0.64 to 0.85) but no effect on infection-
related mortality (OR 1.37 favouring control; 95% CI 0.66 to
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2.82). A number of other meta-analyses have been undertaken by
authors funded by pharmaceutical companies that produce G(M)-
CSFs; this was information not always disclosed in the text of the
meta-analysis but retrieved from other publications by the authors
(Hackshaw 2004; Kuderer 2007; Wittman 2006). These meta-
analyses tended to show a stronger effect of G(M)-CSF in pre-
venting infections and on infection-related mortality than Bohlius
2008, or reported the results as ORs and not as relative risks (RR).
As an example of the former, Bohlius 2008 reported a RR of 1.37
(95%CI 0.66 to 2.82) for the outcome infection-relatedmortality,
from eight trials involving lymphoma patients, as compared with
a RR of 0.58 (95% CI 0.28 to 1.23) reported by Kuderer 2007
from five trials (in the subgroup of patients with lymphoma). For
an example of the latter, for FN in the paediatric population of
Wittman 2006 the OR was 0.59 (recalculated as RR 0.82), which
compares to the RR of 0.82 reported by Sung 2007 for the paedi-
atric patient subgroup.
Antibiotics
In contrast to the prophylactic use of G(M)-CSFs, the prophylac-
tic use of antibiotics in patients with cancer and neutropenia is
more controversial. Several important guidelines are opposed to it
(Lyman 2005; Smith 2006). Prophylaxis using antibiotics targets
potential pathogens only and, in contrast to colony-stimulating
factors, does not deal with the dose-limiting effect of haematolog-
ical toxicity which is particularly relevant for dose-intensification
schemes. A major concern of routine prophylactic use of antibi-
otics in patients with cancer and neutropenia is that it increases
bacterial resistance to these agents, This may, in turn, compromise
the success of treating serious infections in current as well as fu-
ture patients by the spread of (multi)resistance. In addition, hy-
persensitivity reactions, gastrointestinal toxicities, and the promo-
tion of fungal overgrowth after antibiotics put the patient at risk
of potentially serious adverse events. Thus these aspects may limit
their efficacy in reducing infection-related morbidity or mortality
(Carratala 1995; Gafter-Gvili 2007; Somolinos 1992).
During the last decade, prophylaxis with antibiotics was studied
in a number of randomised clinical trials. The evidence provided
was not regarded as entirely convincing because none of the stud-
ies were sufficiently large to provide conclusive evidence on the
real efficacy of prophylaxis (Bucaneve 2005; Cullen 2005; Karp
1987; Lew 1995). Subsequent meta-analyses suggested that pro-
phylaxis using antibiotics reduces the incidence of gram-negative
bacterial infection, total infection, fever episodes, and hospitali-
sation (Cruciani 2003; Engels 1998). Moreover, a recently pub-
lished meta-analysis of data on antibiotic prophylaxis (or more
specifically fluoroquinolones) compared to placebo or no inter-
vention demonstrated that not only infectionswere reduced but all
cause mortality and infection-related mortality were too (Gafter-
Gvili 2005; Leibovici 2006). One important question which is
still unanswered is whether prophylaxis should be considered for
all patients with cancer and neutropenia. In another meta-analysis
on antibiotic prophylaxis the majority of patients were suffering
from haematological malignancies and received high-dose chemo-
therapy and bone marrow transplantation, with only a few studies
focusing on solid tumours (Cullen 2005; Gafter-Gvili 2005). An-
other factor possibly compromising the results of the main meta-
analysis is that studies were included that randomised chemother-
apy cycles and not patients, or reported cycle-based outcomes as
opposed to a true incidence (where the number of patients and
not cycles are analysed). Again, no information on G(M)-CSFs
compared to antibiotics was available from these analyses.
Why it is important to do this review
The best prophylactic treatment of FN in cancer patients receiving
myeloablative chemotherapy remains controversial and, in gen-
eral, international guidelines concentrate on either antibiotics or
G(M)-CSF. The evidence outlined above suggests that prophy-
laxis with an antibiotic might be as effective as with G(M)-CSF
for reducing both infections and mortality. A prospective ran-
domised trial comparing antibiotics versus G(M)-CSF in stage IV
breast cancer patients treated with intermediate-dose chemother-
apy showed no difference between both groups, while the cost of
G(M)-CSF was almost seven times higher than that of the antibi-
otics (Schroder 1999). To our knowledge the present Cochrane
Review is the first systematic review that compares G(M)-CSFs
to antibiotics, even though clinicians are currently faced with the
choice of using G(M)-CSFs, antibiotics, or both.
Often the mortality rates in clinical trials of prophylactic regimes
for FN are too low to allow an accurate assessment of the effect of
prophylaxis on important clinical endpoints such as mortality or
survival (Elting 2002). In this situation, meta-analyses that analyse
much higher numbers of similarly treated patients are a suitable
tool to evaluate the overall effect of regimens that showed statis-
tically insignificant results in (underpowered) clinical trials (Paul
2005). During the systematic assessment of available evidence it
is very important to account for both clinical and methodological
differences in the individual trials, such as the definition of impor-
tant endpoints and the multitude of different prophylaxis sched-
ules. There may also be considerable heterogeneity introduced by
different inclusion and exclusion criteria, or regional differences
in pathogen epidemiology or resistance patterns.
O B J E C T I V E S
To identify, critically evaluate, describe, statistically analyse, and
summarise the evidence regarding the effectiveness of prophylactic
antibiotic treatment compared to prophylactic use of colony stim-
ulating factors in preventing febrile neutropenia (FN), severe in-
fections, infection-related mortality, and overall mortality in can-
cer patients undergoing myelosuppressive chemotherapy. This in-
cludes bone marrow transplantation and stem cell transplantation.
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M E T H O D S
Criteria for considering studies for this review
Types of studies
Only randomised controlled trials comparing G(M)-CSF pro-
phylaxis with antibiotic prophylaxis in cancer patients receiving
myeloablative chemotherapywere included.Non-randomised and
quasi-randomised studies, for example alternate treatment alloca-
tion or allocation by date of birth, were excluded as these study
designs are regarded to be more prone to bias (Higgins 2006).
In addition, trials looking at peri-operative infection prophylaxis,
stem cell mobilisation, and priming of malignant cells with G(M)-
CSFs were excluded.
Types of participants
We planned to include paediatric and adult, male and female pa-
tients with a confirmed diagnosis of any type of cancer who were
undergoing myelosuppressive chemotherapy, bone marrow trans-
plantation, or stem cell transplantation. Both solid and haemato-
logical malignancies were eligible.
Types of interventions
We reviewed trials comparing G(M)-CSF and antibiotics in the
primary prophylaxis of infection-related complications. Trials that
examined pegylated G(M)-CSF (pegfilgrastim) were eligible pro-
vided pegfilgrastim was given once, 24 hours after the completion
of chemotherapy. Trials looking at secondary prophylaxis, defined
as prophylaxis in a patient who suffered from FN in an earlier
course of chemotherapy, were also eligible but a subgroup analy-
sis was planned. No trials examining secondary prophylaxis were
identified. Therapeutic interventions for FN are not part of this
review.
We included studies in which the intended chemotherapy regimen
did not differ between study arms. Therefore, we excluded studies
which compared dose-intensified, dose-accelerated, or dose-dense
regimens with standard chemotherapy as this resulted in different
chemotherapy protocols in the arm that received antibiotic pro-
phylaxis and the arm that received CSF prophylaxis. Trials with
more than two arms were included provided at least two arms with
the relevant comparison had the same chemotherapy protocol.
Types of outcome measures
Primary outcomes
• Overall survival
• Microbiologically or clinically, or both, documented in-
fections
Any definition of clinically documented or microbiologically doc-
umented infections given by authors was accepted. If available,
data on all and not only severe clinically ormicrobiologically docu-
mented infections were extracted. Microbiologically documented
infections were required to have some kind of cultural confirma-
tion of the infection. Infections reported without information on
microbiological confirmation were considered to be clinically doc-
umented infections.
Secondary outcomes
• Severe infections
• Infectious episodes
• Frequency of febrile neutropenia (FN) (any definition
of fever and neutropenia accepted)
• Frequency of fever (any definition)
• All cause mortality (including infection-related, treat-
ment-related, or on-trial mortality)
• Quality of life (QoL)
In patient populations with curative treatment intent, overall sur-
vival is considered to be the most important clinical endpoint.
Studies focusing on the efficacy of prophylaxis only will most
likely have only short follow up, mainly providing information
on early mortality. Determining the cause of death in severely ill
patients can be associated with measurement bias. Therefore, all
cause mortality, comprising infection-related as well as treatment-
related mortality, was extracted.
In patient populations with palliative treatment intent, quality of
life is regarded the most relevant clinical outcome measure and
will thus be analysed as secondary endpoint. Only quality of life
studies using a validated QoL instrument were eligible. No trial
examining quality of life was retrieved.
Search methods for identification of studies
Electronic searches
A systematic and comprehensive search strategy based on the
highly sensitive search filter for randomised controlled trials (
Dickersin 1994) was conducted (1985 to January 2008). The
search covered the Cochrane Central Register of Controlled Tri-
als (CENTRAL) and major medical databases (MEDLINE, EM-
BASE). Proceedings from relevant conferences (American Soci-
ety of Clinical Oncology, American Society of Hematology) were
searched (2000 to 2007).
The search strategy in Appendix 1 was used to searchMEDLINE;
for EMBASE see Appendix 2; and for CENTRAL see Appendix
3.
Searching other resources
In addition, we screened references from identified trials, relevant
reviews, guidelines, and databases of ongoing clinical trials. No
language restriction was applied. In order to avoid publication and
reporting bias, abstract publications and unreported data were eli-
gible for the review. Studies that seemed to meet inclusion criteria
from their title and abstract were retrieved as full text for further
evaluation. It was planned to identify duplicate reports in order to
avoid duplication bias. No duplicate report was retrieved.
Data collection and analysis
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Study selection
Trials were selected if they met the inclusion criteria as specified
above. At every stage of searching and screening the overall number
of studies identified, excluded, and included, with the reasons
given, were documented in a QUOROM flow diagram (Moher
1999).
Assessment of methodological quality
At the level of the single trials
The quality of eligible studies was independently rigorously eval-
uated by two review authors. The following quality components,
which are part of the CONSORT (Moher 2003) statement, were
assessed.
1. Was treatment allocation concealed?
2. Were clinicians and participants blinded to the assigned
treatment?
3. Were outcome assessors blinded to the assigned treat-
ment?
4. Were number of withdrawals, drop outs, and losses to
follow up in each group stated; and were the numbers
less than 10% and equally distributed between arms?
5. Were the participants included in the analyses as part
of the groups to which they were allocated (intention-
to-treat analysis)?
Full-text versions of eligible studies were used to obtain data.
Where these did not provide sufficient information, authors were
contacted for further details. Furthermore, trials were classified
as high quality trials (allocation concealment, intention-to-treat
analysis with less than 10% loss, and a ratio of loss of less than 2:1
between arms) and low quality trials (not fulfilling at least one of
the criteria for high quality) for a sensitivity analysis.
Data extraction
Data from the studies were extracted by two review authors (per
study) using a standardised data extraction form that contained
the following items.
1. General information: author, title, source, publication
date, publication type (full text, abstract, unpublished).
2. Study characteristics: trial design, interventions, setting,
trial dates, inclusion and exclusion criteria, comparabil-
ity of groups, treatment allocation, blinding, subgroup
analysis, statistics, power calculations, length of follow
up, study quality, funding source.
3. Participant characteristics: age; diagnosis; stage of dis-
ease; prior treatments; number of participants recruited,
allocated, and evaluated; participants lost to follow up;
noticeable differences in risk factors for developing FN.
4. Interventions: duration; type; dose and timingofG(M)-
CSF, antibiotics, and other infection prophylaxis (e.g.
antimycotics); concomitant treatment (setting, dura-
tion, type of chemotherapy); and supportive care (e.g.
type of empirical antibiotic therapy).
5. Outcomes:
i) primary: overall survival (results of a survival
analysis with time included in the analysis),
microbiologically or clinically, or both, doc-
umented infections;
ii) secondary:
severe infections, infectious episodes, QoL,
frequency of FN, frequency of fever, all cause
mortality as a binary outcome (including in-
fection-related, treatment-related, and early
mortality).
Publications reporting on more than one trial would have been
extracted using one data extraction form for each trial. Trials re-
ported on inmore than one publication would have been extracted
on one form only. Extracted data were checked by a second review
author. Data entry into statistical software was done by one author
and checked for accuracy by a second author.
During the above steps (study selection, assessment of method-
ological quality, data extraction) potential disagreements between
the review authors were resolved by consensus. If an agreement
was not reached, a third review author was asked to give his or her
opinion.
Data analysis
For statistical analysis, data were entered into Review Manager
5.0. Additional analyses that were not possible with RevMan were
planned to be done in the statistical package SAS 9.12. Since no
meta-analysis was possible, no further analyses were done.
Should future updates allow a meta analysis, data will be anal-
ysed as follows. All effect estimates will be obtained separately for
each study and then pooled using the Mantel-Haenszel method.
A fixed-effect model will be used to calculate an overall treatment
effect in meta-analysis. For all analyses corresponding 95% confi-
dence intervals (CI) will be calculated. Time-to-event data (over-
all survival) will be calculated as hazard ratios (HR) based on the
method introduced by Parmar (Parmar 1998; Tierney 2007). For
binary data the relative risk (RR) will be used. Numbers needed
to treat to benefit (NNTB) and numbers needed to treat to harm
(NNTH) will be calculated for ease of interpretation.
The extent of heterogeneity between trials will be tested using a
Chi2 statistic with the significance level set at P < 0.10. The I²
statistic will be used to quantify possible heterogeneity (I² > 25%
moderate heterogeneity, I² > 75% high heterogeneity). Expected
causes of heterogeneitywill be explored by sensitivity and subgroup
analyses. If numbers of included studies allow, a linear regression
test for publication bias will be conducted; a P value of less than
0.1 will be considered significant for this test. A funnel plot will
be generated for visual inspection (Egger 1997; Lau 2006).
Sensitivity analyses (if possible) will be performed for: the overall
quality of the studies (high or low), answers to the quality assess-
ment questions mentioned above, duration of study, publication
type, and whether the study was designed to measure overall sur-
vival.
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Subgroup analyses for the main outcomes, survival and
infections
Subgroup analyses will be performed for different types of un-
derlying malignant disease, different baseline risk for febrile neu-
tropenia or infection, study setting (in-patients or out-patients),
different type of treatment (for example haematologic stem cell
transplantation versus standard chemotherapy), different types of
G(M)-CSFs used, age, and according to whether regimens in-
cluded antimycotic prophylaxis.
Interpretation of data reviewed
Conclusions will be based on the evidence reviewed and discussed
thoroughly with the review authors. Results will be updated every
two years.
R E S U L T S
Description of studies
See:Characteristics of included studies; Characteristics of excluded
studies.
Results of the search
The literature searchwas designed to find all relevant articles where
antibiotics or G(M)-CSFs were used as prophylactic agents. Thus
10,924 abstracts were screened, 473 full texts evaluated briefly,
and 44 considered for the review. Only two trials were included
in the review. For a QUOROM-diagram see Figure 1.
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Figure 1. QUORUM-Diagram
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Included studies
Two studies fulfilled the entry criteria of this review. Both of the
studies involved adults with solid tumours (small cell lung cancer
and breast cancer) and compared prophylaxis for at least six cycles
(Schroder 1999; Sculier 2001). A total of 195 patients, 40 from
Schroder 1999 and 155 from Sculier 2001, were included in this
review. In both studies oral antibiotics were compared to regular
subcutaneous injections of G-CSF (Schroder 1999) or GM-CSF
(Sculier 2001) without blinding of the study participants. Two
different antibiotics were used: a combination of ciprofloxacin and
amphotericin B with an anti-fungal agent (Schroder 1999), and
cotrimoxazole (Sculier 2001).
The study by Sculier 2001 was a three-arm study comparing stan-
dard three-week epirubicin 90mg/m2 , vindesine 3 mg/m2, and
ifosfamide 5mg/m2 (EVI), given intravenously on day one, with
antibiotic prophylaxis in one arm to intensive two-week EVI (same
dosages) given every two weeks (intensive two-week EVI) with
GM-CSF in one arm and antibiotic support in another arm. Only
the two arms with the intensive two-week EVI protocol were in-
cluded in the review. For the purpose of this review the standard
three-week EVI arm with antibiotic prophylaxis was excluded as
there was no possible comparison to a study arm that receivedCSF
prophylaxis with the same chemotherapy protocol. Overall sur-
vival for up to 1000 days, relative and absolute dose intensity, and
adverse events including the incidence of documented infections
were reported.
The Schroder 1999 study randomised chemotherapy-naive pa-
tients receiving three, three-week courses of intravenous cyclo-
phosphamide (1500 mg/m2), epirubicin (80 mg/m2), and 5-flu-
ouracil (1500 or 1000 mg/m2) given on day one; followed by
three cycles of intravenous cyclophosphamide (1500 mg/m2), 5-
fluouracil (600 mg/m2) on day one and intravenous methotrexate
(1500 mg/m2) on day two.
Sculier 2001 administered cotrimoxazole, 160 mg trimethoprim,
and 800 mg sulfamethoxazole three times per day, from day three
through to the end of each cycle in the antibiotic group. Schroder
1999 used two prophylactic agents in the antibiotic prophylaxis
group, a combination of ciprofloxacin (250 mg twice daily) and
amphotericin B (500 mg four times per day) on days three through
to day 17 of each cycle. The GM-CSF dosage was 5 µg/kg subcu-
taneously from day three through to day 13, or until neutrophils
reached 1000/mm3 , in the Sculier 2001 trial; and 263 µg subcu-
taneous G-CSF (lenograstim) on days 3 through to day 12 of each
cycle in the Schroder 1999 trial.
In the Schroder 1999 study episodes of hospitalisation for FN,
as well as their durations, and episodes of grade four leukopenia
were reported. Infection-related mortality was reported by both
Schroder 1999 and Sculier 2001; overall survival, including on-
trial mortality, was reported only by Sculier 2001. The only out-
come reported by both studies was infection-related mortality.
Excluded studies
We excluded 36 trials that compared antibiotic and G-CSF pro-
phylaxis to antibiotic prophylaxis alone, from either full-text in-
formation or further information obtained from the authors (
Ardizzoni 1994; Bradstock 2001; Burton 2006; Clarke 1999;
Dibenedetto 1995; Faber 2006; Geissler 1997; Gonzalez-Vicent
2004; Greenberg 1996; Gulati 1992; Jones 1996; Heath 2003;
Heil 1997; Lee 1998; Little 2002; McQuaker 1997; Michel
2000; Miles 1994; Nemunaitis 1995; Nolan 2007; Ojeda 1999;
Ottmann 1995; Patte 2002; Pettengell 1992; Piccirillo 1999;
Przepiorka 2001; Pui 1997; Schmitz 2004; Spitzer 1994; Stahel
1994; Timmer-Bonte 2005; Trigg 2000; Welte 1996; Witz 1998;
Yau 1996; Zinzani 1997). Similarly, we excluded four trials that
compared antibiotic prophylaxis plus G(M)-CSF to G(M)-CSF
prophylaxis alone (Garcia 2000; Garcia-Saenz 2002; Lalami 2004;
Maiche 1993). One trial was excluded because the chemotherapy
(with either G-CSF prophylaxis or antibiotic prophylaxis) differed
in the two arms (Tjan-Heijnen 2003). We also excluded one non-
randomised comparison (von Minckwitz 2008).
Risk of bias in included studies
Allocation
Both trials were described as randomised but the randomisation
procedure was only reported by Sculier 2001 (minimisation tech-
nique). The multi-centre Sculier 2001 study reported central ran-
domisation.
Blinding
There was no blinding in either of the studies due to the use of
either an oral antibiotic or subcutaneous injections of G(M)-CSF;
no information was given about whether or not the assessors were
blinded.
Selective reporting
At baseline, the distribution of prognostic factors, such as age and
stage of disease, were well balanced in both groups of the two
studies; only limited information was given by Schroder 1999.
Withdrawals and losses to followupwere stated in the Sculier 2001
study and this study also reported intention-to-treat analysis of the
various outcomes. The Schroder 1999 study used a per protocol
analysis in the sense that courses of chemotherapy with incorrectly
administered study drugs were excluded from the analysis.
Effects of interventions
Primary outcome measures
Overall survival
The Kaplan-Meier curves of all three arms, that is the standard-
dose antibiotic prophylaxis arm, the dose-dense antibiotic prophy-
laxis arm, and the dose-dense GM-CSF arm, were identical for
the (maximum) duration of observation of 1000 days reported in
the Sculier 2001 trial. This was despite dose intensification not
being successful in the dose-dense antibiotic arm (the received
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dose intensity was equivalent to the dose intensity of the standard
treatment protocol). The two-year survival was identical, with 6%
surviving in each of the dose-dense arms.
Microbiologically or clinically documented infections
Only Sculier 2001 reported the incidence of documented infec-
tions, with infections in 17/78 patients receiving GM-CSF and
11/77 in patients receiving cotrimoxazole (RR 1.53; 95% CI 0.77
to 3.04 for antibiotics, number needed to treat to benefit (NNTB)
13). This corresponded to a trend towards an increased risk of
infection in patients receiving GM-CSF. A clear definition of doc-
umented infections was not given in the full-text publication of
the trial.
Secondary outcome measures
Incidence of severe infections
Sculier 2001 reported the number of grade III and IV infectious
episodes (classification system not mentioned) but not the inci-
dence of infections.
Infectious episodes
Sculier 2001 described the total number of infectious episodes as
64/360 cycles (18%) in the GM-CSF group and 41/334 cycles
(12%) in the cotrimoxazole group. An OR with CIs was not cal-
culated because the cycles were linked observations.
Quality of life (QoL)
Not reported.
Incidence of febrile neutropenia (FN)
Schroder 1999 reported hospitalisations for FN in 7/18 patients
receiving G-CSF and in 7/22 patients receiving ciprofloxacin and
amphotericin B (RR 1.22; 95% CI 0.53 to 2.84 for antibiotics,
NNTB14). This corresponded to a trend towards an increased risk
of febrile leukopenia in the group receiving G-CSF. Similar results
yet slightly more in favour of ciprofloxacin and amphotericin B
were reported for the analysis of courses of chemotherapy with
febrile leukopenia.
Incidence or episodes of fever
Not reported.
Infection-related mortality
Infection-related mortality was the same in both groups of the
Schroder 1999 trial: no patient died of infectious causes during the
18-week duration of the trial. In the Sculier 2001 trial infection-
related mortality was similar between the two groups with 3/78
infection-related deaths observed in theGM-CSFgroup compared
to 3/77 deaths in the cotrimoxazole group (OR 0.99; 95% CI
0.21 to 4.74).
Treatment-related or early mortality
The 100-day mortality was similar in both groups in the Sculier
2001 trial with 7/78 deaths in the GM-CSF group compared to
5/77 deaths in the dose-dense antibiotic group (OR 1.38; 95%
CI 0.46 to 4.17 for antibiotics, NNTB 40). This included both
early deaths due to cancer and infection-related deaths.
Due to the differences in the outcomes reported (incidence of doc-
umented infections versus episodes of FN) and the lack of infec-
tious deaths in the Schroder 1999 trial no meta-analysis of the re-
sults was attempted. Note, however, that both trials reported sim-
ilar but not statistically significant reductions of either infections
or FN in the antibiotic arm of the study.
D I S C U S S I O N
Summary of main results
The striking finding of this review is that there are very few studies
comparing antibiotics to granulocyte (and macrophage) colony
stimulating factors (G(M)-CSF) for infection prophylaxis in can-
cer patients receiving myelosuppressive chemotherapy or stem cell
transplantation.
Overall completeness and applicability of
evidence
Two trials were identified. Both were in patients with solid can-
cer and both demonstrated a trend towards a smaller number of
infections in the group receiving antibiotics. However, in one of
the two trials the chemotherapy dose intensity received by the an-
tibiotic comparison group was much lower than in the GM-CSF
group (Sculier 2001), which may explain the increased incidence
of infections in the latter group. The lower dose intensity did not
negatively affect overall survival.
Agreements and disagreements with other
studies or reviews
The latest and most comprehensive meta-analysis of G(M)-CSF
versus control (Sung 2007) includes over 80 trials with more than
12,000 patients for the outcome all cause mortality. Similarly
the most comprehensive antibiotics versus control meta-analysis
(Gafter-Gvili 2005) includes 49 trials with more than 6000 pa-
tients (for the outcome all cause mortality). The low number of
trials directly comparing antibiotics to G(M)-CSFs is surprising
considering the higher cost of G(M)-CSFs compared to standard
antibiotics. However, a high number of trials comparing G(M)-
CSFs to control received funding from pharmaceutical compa-
nies that produce G(M)-CSFs. In both of the trials included in
this review there was a trend towards the reduction of infections
or febrile leukopenia in patients receiving antibiotic prophylaxis,
and not G(M)-CSFs. Clearly more trials with larger numbers of
patients are required to answer this question, in particular with
regard to early infection-related mortality.
Limited data also exists from a non-randomised comparison
within a randomised controlled trial by von Minckwitz 2008. In
the randomised controlled trial reported by von Minckwitz 2008
the supportive care in this breast cancer study changed over time.
This study was based primarily on the chemotherapy regimen of
docetaxel, doxorubicin, and cyclophosphamide (TAC) and, de-
pending on the initial response rate, patients were randomised to
different numbers of cycles of TAC or to TAC compared to vi-
norelbine and capecitabine (NX). In patients receiving TAC, the
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incidence of febrile leukopenia was similar in patients receiving
cotrimoxazole alone and daily injections of G-CSF, while patients
receiving pegfilgrastim alone or pegfilgrastim and antibiotics had
fewer episodes of FN. Interestingly this analysis was sponsored by
a pharmaceutical company producing pegfilgrastim and only the
TAC arm, and not patients receiving NX, were analysed; which
makes publication bias with regard to the chemotherapy arms a
possibility. In addition, missing data led to the exclusion of one
third of the patients, again possibly compromising the results.
While a recent meta-analysis showed that pegfilgrastim is superior
to filgrastim (Pinto 2007), no randomised information is available
for pegfilgrastim versus antibiotics.
Looking at this limited evidence, the recent recommendations of
the ASCO and EORTC guidelines (Aapro 2006; Smith 2006)
where antibiotic prophylaxis (not even with or without G(M)-
CSF prophylaxis) is not mentioned are surprising. An argument
against antibiotic prophylaxis is the occurrence of resistant strains
of bacteria.However, this argument is only valid if theG(M)-CSFs
are not (much) worse than antibiotics in the first place - a point yet
to be proven.The summary estimates of the reductionof infections
(or fever, which is less prone to masking of bacterial infection
through the prophylaxis used) is higher in the systematic review
of antibiotics versus control than the systematic review for G(M)-
CSFs versus control. Such an indirect comparison requires a careful
analysis of the supportive care used, the patient populations, and
study designs of the included trials. This work is underway and
will be published outside The Cochrane Library.
A U T H O R S ’ C O N C L U S I O N S
Implications for practice
Both antibiotics and granulocyte (and macrophage) colony stim-
ulating factors are successful in reducing infections in cancer pa-
tients receiving myeloablative chemotherapy; see other meta-anal-
yses (for example Gafter-Gvili 2005; Sung 2007). However, as ex-
amined here there is insufficient direct evidence from randomised
controlled trials to recommend one over the other.
Implications for research
Large, high quality trials comparing antibiotic prophylaxis to in-
fection prophylaxis usingG(M)-CSFs are necessary in awide range
of cancer patients.
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C H A R A C T E R I S T I C S O F S T U D I E S
Characteristics of included studies [ordered by study ID]
Schroder 1999
Methods Chemotherapy regimen (3 week cycle): cyclophosphamide 1500 mg/m2, epirubicin 80 mg/m2, F-FU
1000mg/m2 on day one of the first six cycle then cyclophosphamide 1500 mg/2, 5-FU 600mg/m2 on day
one and iv methotrexate 1500mg/m2 on day two for additional 3 cycles
Participants 40 patients with de novo metastatic breast cancer, age < 65 years
Interventions Antibiotic arm: oral ciprofloxacin 2 X 250mg daily + oral amphotericin B 100mg/ml 4 X 5ml daily on
days 3 through 17
Outcomes episodes of hospitalisation for febrile neutropenia, duration of hospitalisation for febrile neutropenia, grade
four leucopenia
Notes No blinding (oral versus sc injections)
Risk of bias
Item Authors’ judgement Description
Blinding?
All outcomes
No
Sculier 2001
Methods 3 arm study: standard 3 week chemotherapy regimen, intensive 2 week chemotherapy regimen with
antibiotic or G-CSF support. Chemotherapy regimen (6 cycles): epirubicin 90mg/m2, vindesine 5mg/m2,
ifosfamide 5mg/m2
Participants Untreated extensive disease small cell lung cancer, age < 75 y, adequate haematological, renal and hepatic
function, no recent myocardial infarction or congestive heart failure, performance status (Karnovski >=
60)
Interventions Antibiotic arm: trimethoprim 160mg/sulfamethoxale 800mg orally every 12 hours from day 3 of the first
course of chemotherapy until the end of the courses. GM-CSF arm: 5µg/kg GM-CSF (Leucomax) from
day 3 to 13 of each cycle or until ANC > 1000/µl
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Sculier 2001 (Continued)
Outcomes Absolute and relative dose intensity, response rate, overall survival, adverse events, incidence of infections
and severe infections
Notes Only the intensive chemotherapy regimen included in meta-analysis. No blinding (oral medication versus
sc injections)
Risk of bias
Item Authors’ judgement Description
Allocation concealment? Yes
Blinding?
All outcomes
No
Characteristics of excluded studies [ordered by study ID]
Ardizzoni 1994 Comparison of G(M)-CSF plus antibiotics versus antibiotics alone
Bradstock 2001 Comparison of G(M)-CSF plus antibiotics versus antibiotics alone
Burton 2006 Comparison of G(M)-CSF plus antibiotics versus antibiotics alone
Clarke 1999 Comparison of G(M)-CSF plus antibiotics versus antibiotics alone
Dibenedetto 1995 Comparison of G(M)-CSF plus antibiotics versus antibiotics alone
Faber 2006 Comparison of G(M)-CSF plus antibiotics versus antibiotics alone
Garcia 2000 Comparison of antibiotics plus G(M)-CSF versus G(M)-CSF alone
Garcia-Saenz 2002 Comparison of antibiotics plus G(M)-CSF versus G(M)-CSF alone
Geissler 1997 Comparison of G(M)-CSF plus antibiotics versus antibiotics alone
Gonzalez-Vicent 2004 Comparison of G(M)-CSF plus antibiotics versus antibiotics alone
Greenberg 1996 Comparison of G(M)-CSF plus antibiotics versus antibiotics alone
Gulati 1992 Comparison of G(M)-CSF plus antibiotics versus antibiotics alone
Heath 2003 Comparison of G(M)-CSF plus antibiotics versus antibiotics alone
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(Continued)
Heil 1997 Comparison of G(M)-CSF plus antibiotics versus antibiotics alone
Jones 1996 Comparison of G(M)-CSF plus antibiotics versus antibiotics alone
Lalami 2004 Comparison of antibiotics plus G-CSF versus G-CSF alone
Lee 1998 Comparison of G(M)-CSF plus antibiotics versus antibiotics alone
Little 2002 Comparison of G(M)-CSF plus antibiotics versus antibiotics alone
Maiche 1993 Comparison of antibiotics plus G-CSF versus G-CSF alone
McQuaker 1997 Comparison of G(M)-CSF plus antibiotics versus antibiotics alone
Michel 2000 Comparison of G(M)-CSF plus antibiotics versus antibiotics alone
Miles 1994 Comparison of G(M)-CSF plus antibiotics versus antibiotics alone
Nemunaitis 1995 Comparison of G(M)-CSF plus antibiotics versus antibiotics alone
Nolan 2007 Comparison of G(M)-CSF plus antibiotics versus antibiotics alone
Ojeda 1999 Comparison of G(M)-CSF plus antibiotics versus antibiotics alone
Ottmann 1995 Comparison of G(M)-CSF plus antibiotics versus antibiotics alone
Patte 2002 Comparison of G(M)-CSF plus antibiotics versus antibiotics alone
Pettengell 1992 Comparison of G(M)-CSF plus antibiotics versus antibiotics alone
Piccirillo 1999 Comparison of G(M)-CSF plus antibiotics versus antibiotics alone
Przepiorka 2001 Comparison of G(M)-CSF plus antibiotics versus antibiotics alone
Pui 1997 Comparison of G(M)-CSF plus antibiotics versus antibiotics alone
Schmitz 2004 Comparison of G(M)-CSF plus antibiotics versus antibiotics alone
Spitzer 1994 Comparison of G(M)-CSF plus antibiotics versus antibiotics alone
Stahel 1994 Comparison of G(M)-CSF plus antibiotics versus antibiotics alone
Timmer-Bonte 2005 Comparison of G(M)-CSF plus antibiotics versus antibiotics alone
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(Continued)
Tjan-Heijnen 2003 4-arm study, two with intensive chemotherapy (G-CSF versus G-CSF + antibiotics) and two with standard
dose chemotherapy (control versus antibiotics). Excluded due to the differences in the chemotherapy regi-
mens between antibiotics and G-CSF.
Trigg 2000 Comparison of G(M)-CSF plus antibiotics versus antibiotics alone
Welte 1996 Comparison of G(M)-CSF plus antibiotics versus antibiotics alone
Witz 1998 Comparison of G(M)-CSF plus antibiotics versus antibiotics alone
Yau 1996 Comparison of G(M)-CSF plus antibiotics versus antibiotics alone
Zinzani 1997 Comparison of G(M)-CSF plus antibiotics versus antibiotics alone
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D A T A A N D A N A L Y S E S
This review has no analyses.
A P P E N D I C E S
Appendix 1. MEDLINE search strategy
1. exp ANTI-BACTERIAL AGENTS/
2. (antibacterial$ or anti-bacterial$).tw,kf,ot.
3. antibio$.tw,kf,ot.
4. (antimicrobial$ or anti-microbial$).tw,kf,ot.
5. (anti-mycobacterial$ or antimycobacterial$).tw,kf,ot.
6. bacteriocid$.tw,kf,ot.
7. (selective$ adj3 decontaminat$).tw,kf,ot.
8. ANTIBIOTIC PROPHYLAXIS/
9. exp QUINOLONE/
10. fluoroquinolones$.tw,kf,ot.
11. ciprofloxa#in$.tw,kf,ot.
12. ofloxa#in$.tw,kf,ot.
13. norfloxa#in$.tw,kf,ot.
14. enoxa#in$.tw,kf,ot.
15. pefloxa#in$.tw,kf,ot.
16. exp TRIMETHOPRIM/
17. trimethoprim$.tw,kf,ot.
18. sulfamethoxazol$.tw,kf,ot.
19. trimethoprim-sulfamethoxazol$.tw,kf,ot.
20. tmp-smz$.tw,kf,ot.
21. exp POLYMYXINS/
22. colistin$.tw,kf,ot.
23. (nalidixic$ adj3 acid$).tw,kf,ot.
24. polymyxin$.tw,kf,ot.
25. AMINOGLYCOSIDES/
26. GENTAMICINS/
27. gentami#in$.tw,kf,ot.
28. exp NEBRAMYCIN/
29. tobramy#in$.tw,kf,ot.
30. NEOMYCIN/
31. neomy#in$.tw,kf,ot.
32. VANCOMYCIN/.
33. vancomy#in$.tw,kf,ot.
34. ROXITHROMYCIN/
35. roxithromy#in$.tw,kf,ot.
36. RIFAMPIN/
37. (rifampin$ or rifampicin$).tw,kf,ot.
38. BETA-LACTAMS/
39. beta-lactam$.tw,kf,ot.
40. PENICILLINS/
41. peni#illin$.tw,kf,ot.
42. AMOXICILLIN/
43. amoxi#illin$.tw,kf,ot.
44. CEPHALOTHIN/
45. (cephalot?in$ or cefalot?in$).tw,kf,ot.
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46. CEFTRIAXONE/
47. ceftriaxone$.tw,kf,ot.
48. TICARCILLIN/
49. ticar#illin$.tw,kf,ot.
50. framycetin$.tw,kf,ot.
51. or/1-50
52. COLONY-STIMULATING FACTORS/
53. exp COLONY-STIMULATING FACTORS, RECOMBINANT/
54. exp GRANULOCYTE COLONY STIMULATING FACTOR, RECOMBINANT/
55. exp GRANULOCYTE COLONY-STIMULATING FACTOR/
56. exp GRANULOCYTE-MACROPHAGE COLONY-STIMULATING FACTOR/
57. MACROPHAGE COLONY-STIMULATING FACTOR/
58. (rhg?csf$ or rhgm?csf$).tw,kf,ot.
59. (rmethug$ or rhmethug$).tw,kf,ot.
60. (rhug$ or rhugm$).tw,kf,ot.
61. (gcsf$ or g-csf$).tw,kf,ot.
62. (gm-csf$ or gmcsf$).tw,kf,ot.
63. (granulo?yt$ adj3 fa#tor$).tw,kf,ot.
64. (ma#rophag$ adj5 fa#tor$).tw,kf,ot.
65. csf.ti.
66. FILGRASTIM$.tw,hw,nm,kf.
67. NEUPOGEN$.tw,hw,nm,kf.
68. LENOGRASTIM$.tw,hw,nm,kf.
69. GRANOCYTE$.tw,hw,nm,kf.
70. EUPROTIN$.tw,hw,nm,kf.
71. PEG?FILGRASTIM$.tw,hw,nm,kf.
72. NEULASTA$.tw,hw,nm,kf.
73. LEUKINE$.tw,hw,nm,kf.
74. MOLGRAMOSTIN$.tw,hw,nm,kf.
75. Mielogen$.tw,kf,ot.
76. LEUCOMAX$.tw,hw,nm,kf.
77. or/52-76
78. 51 or 77
79. *LEUKOPENIA/
80. exp AGRANULOCYTOSIS/
81. granulocytopen$.tw,kf,ot.
82. agranulocyto$.tw,kf,ot.
83. neutropen$.tw,kf,ot.
84. leu#open$.tw,kf,ot.
85. (aplasia or aplastic or aplasion).tw,kf,ot.
86. (leukocyt$ adj5 nadir).tw,ot.
87. (neutrophil$ adj5 nadir).tw,ot.
88. INFECTION/
89. infect$.tw,kf,ot.
90. SEPSIS/
91. (septicem$ or septicaem$).tw,kf,ot.
92. (bacteraem$ or bacterem$).tw,kf,ot.
93. FEVER/
94. fever$.tw,kf,ot.
95. pyrexia$.tw,kf,ot.
96. “Fever of Unknown Origin”/
97. (fever adj4 (unknown adj3 origin)).tw,kf,ot.
98. PNEUMONIA/
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99. ((lung$ or pulmon$) and inflammation$).tw,kf,ot.
100. pneumonit$.tw,kf,ot.
101. engraftment$.tw,kf,ot.
102. (neutrophil$ adj3 recover$).tw,kf,ot.
103. (haematolog$ adj3 recover$).tw,kf,ot.
104. (hematolog$ adj3 recover$).tw,kf,ot.
105. or/79-104
106. exp NEOPLASMS BY HISTOLOGIC TYPE/
107. exp NEOPLASMS BY SITE/
108. neoplas$.tw,kf,ot.
109. tumo?r$.tw,kf,ot.
110. (krebs$ or cancer$).tw,kf,ot.
111. malignan$.tw,kf,ot.
112. (carcino$ or karzino$).tw,kf,ot.
113. karzinom$.tw,kf,ot.
114. sarcom$.tw,kf,ot.
115. leuk#?m$.tw,kf,ot.
116. lymphom$.tw,kf,ot.
117. melano$.tw,kf,ot.
118. metastas$.tw,kf,ot.
119. (mesothelio$ or mesotelio$).tw,kf,ot.
120. carcinomatos$.tw,kf,ot.
121. (gliom$ or glioblastom$).tw,kf,ot.
122. osteo?sarcom$.tw,kf,ot.
123. (blastom$ or neuroblastom$).tw,kf,ot.
124. or/106-123
125. 105 and 124
126. 78 and 125
127. randomized controlled trial.pt.
128. controlled clinical trial.pt.
129. RANDOMIZED CONTROLLED TRIALS/
130. RANDOM ALLOCATION/
131. DOUBLE BLIND METHOD/
132. SINGLE BLIND METHOD/
133. or/127-132
134. (ANIMALS not HUMANS)/
135. 133 not 134
136. clinical trial.pt.
137. exp CLINICAL TRIALS/
138. (clin$ adj25 trial$).ti,ab.
139. ((singl$ or doubl$ or trebl$ or tripl$) adj25 (blind$ or mask$)).ti,ab.
140. PLACEBOS/
141. placebo$.ti,ab.
142. random$.ti,ab.
143. RESEARCH DESIGN/
144. or/136-143
145. 144 not 134
146. 145 not 135
147. COMPARATIVE STUDY/
148. exp EVALUATION STUDIES/
149. FOLLOW UP STUDIES/
150. PROSPECTIVE STUDIES/
151. (control$ or prospectiv$ or volunteer$).ti,ab.
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152. or/143-147
153. 152 not 134
154. 153 not (135 or 146)
155. 135 or 146 or 154
156. 126 and 155
Appendix 2. EMBASE search strategy
1 exp ANTI-BACTERIAL AGENTS/
2 (antibacterial? OR anti-bacterial?).tw.
3 antibio?.tw.
4 (antimicrobial? OR anti-microbial?).tw.
5 (anti-mycobacterial? OR antimyocobacterial?).tw.
6 bacteriocid?.tw.
7 (selective ADJ3 decontaminat?).tw.
8 ANTIBIOTIC PROPHYLAXIS/
9 exp QUINOLONE/
10 fluoroquinilones?.tw.
11 ciprofloxa#in?.tw.
12 ofloxa#in?.tw.
13 norfloxa#in?.tw.
14 enoxa#in?.tw.
15 pefloxa#in?.tw.
16 exp TRIMETHOPRIM/
17 trimethoprim?.tw.
18 sulfamethoxazol?.tw.
19 (trimethoprim-sulfamethoxazol? OR (trimethoprim ADJ3 sulfamethoxazol?)).tw.
20 tmp-smz?.tw.
21 exp POLYMYXIN/
22 colistin?.tw.
23 (nalidixic? ADJ3 acid?).tw.
24 polymyxin?.tw.
25 AMINOGLYCOSIDE/
26 GENTAMICIN/
27 gentami#in?.tw.
28 exp NEBRAMYCIN/
29 tobramy#in?.tw.
30 NEOMYCIN/
31 neomy#in?.tw.
32 VANCOMYCIN/
33 vancomy#in?.tw.
34 ROXITHROMYCIN/
35 roxithromy#in?.tw.
36 RIFAMPIN/
37 (rifampin? OR rifampicin?).tw.
38 BETA-LACTAMS/
39 PENICILLINS/
40 AMOXICILLIN/
41 CEPHALOTHIN/
42 CEFTRIAXONE/
43 TICARCILLIN/
44 (beta-lactam? OR beta$ lactam$).tw.
45 peni#illin?.tw.
46 amoxi#illin?.tw.
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47 (cephalot#in? OR cefalot#in?).tw.
48 ceftriaxone?.tw.
49 ticar#illin?.tw.
50 framycetin?.tw.
51 OR/ 1-50
52 COLONY-STIMULATINGING FACTORS/
53 exp COLONY-STIMULATING FACTORS, RECOMBINANT/
54 exp GRANULOCYTE COLONY STIMULATING FACTOR, RECOMBINANT/
55 exp GRANULOCYTE COLONY-STIMULATING FACTOR/
56 GRANULOCYTE-MACROPHAGE COLONY-STIMULATING FACTOR/
57 MACROPHAGE COLONY-STIMULATING FACTOR/
58 (rhg#csf? OR rhgm#csf?).tw.
59 (rmethug? OR rhmethug?).tw.
60 (rhug? OR rhugm?).tw.
61 (gcsf? OR g-csf?).tw.
62 (gm-csf? OR gmcsf?).tw.
63 (granulo#yt? ADJ3 fa#tor?).tw.
64 (ma#rophag? ADJ5 fa#tor?).tw.
65 csf.ti
66 filgrastim?.tw.
67 neupogen?.tw.
68 lenograstim?.tw.
69 euprotin?.tw.
70 granocyte?.tw.
71 peg#filgrastim?.tw.
72 neulasta?.tw.
73 leukine?.tw.
74 molgramostine?.tw.
75 mielogen?.tw.
76 leucomax?.tw.
77 OR/ 52-76
78 * LEUKOPENIA/
79 exp AGRANULOCYTOSIS/
80 granulocytopen?.tw.
81 agranulocyto?.tw.
82 neutropen?.tw.
83 leu#open?.tw.
84 (aplasia OR aplastic OR aplasion).tw.
85 leukocyt? ADJ5 nadir).tw.
86 (neutrophil? ADJ5 nadir).tw.
87 INFECTION/
88 infect?.tw.
89 SEPSIS/
90 (septicemia? OR septicaemia?).tw.
91 (bacteraem? OR bacterem?).tw.
92 FEVER/
93 pyrexia.tw.
94 fever?.tw.
95 FEVER OF UNKNOWNORIGIN/
96 (fever ADJ4 (unknown ADJ3 origin)).tw.
97 PNEUMONIA/
98 ((lung? OR pulmonary?) AND inflammation?).tw.
99 pneumonitis?.tw.
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100 engraftment?.tw.
101 (neutrophil? ADJ3 recover?).tw.
102 (hematolog? ADJ3 recover?).tw.
103 (haematology? ADJ3 recover?).tw.
104 OR/ 78-103
105 exp NEOPLASMS BY HISTOLOGIC TYPE/
106 exp NEOPLASMS BY SITE/
107 neoplas?.tw.
108 (tumor? OR tumour?).tw.
109 (krebs? OR cancer?).tw.
110 malignan?.tw.
111 (carcino? OR karzino?).tw.
112 karzinom?.tw.
113 sarcom?.tw.
114 (leukaem? OR leukem?).tw
115 lymphom?.tw.
116 melano?.tw.
117 metastas?.tw.
118 (mesothelio? OR mesotelio?).tw.
119 carcinomatos?.tw.
120 (gliom? OR glioblastom?).tw.
121 osteo?sarcom?.tw.
122 OR/ 105-121
123 CLINICAL TRIAL/
124 RANDOMIZED CONTROLLED TRIALS/
125 RANDOM ALLOCATION/
126 SINGLE-BLIND METHOD/
127 DOUBLE-BLIND METHOD/
128 CROSS-OVER STUDIES/
129 PLACEBOS/
130 Randomi?ed controlled trial$.tw.
131 RCT.tw.
132 random allocation.tw.
133 randomly allocated.tw.
134 Allocated randomly.tw.
135 (allocated ADJ2 random).tw.
136 (allocated ADJ2 random).tw.
137 single blind$.tw.
138 double blind$.tw.
139 ((treble or triple) ADJ blind$).tw.
140 placebo$.tw.
141 PROSPECTIVE STUDIES/
142 OR/ 123-141
143 CASE STUDY/
144 case report.tw.
145 ABSTRACT REPORT/ OR LETTER/
146 OR/ 143-145
147 142 NOT 146
148 ANIMAL/
149 HUMAN/
150 148 NOT 149
151 147 NOT 150
152 51 OR 77
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153 104 AND 122
154 152 AND 153
155 154 AND 51
Appendix 3. CENTRAL search strategy
#1 MeSH descriptor Anti-Bacterial Agents explode all trees
#2 (antibacterial*) OR (anti-bacterial*)
#3 (antibio*)
#4 (antimicrobial*) OR (anti-microbial*) OR (anti-mycobacterial*) OR (antimyocobacterial*) OR (bacteriocid*) OR (selective
NEAR/3 decontaminat*)
#5 MeSH descriptor Antibiotic Prophylaxis explode all trees
#6 MeSH descriptor Quinolones explode all trees
#7 (fluoroquinilones) OR (ciprofloxa*in*) OR (ofloxa*in*) OR (norfloxa*in*) OR (enoxa*in*) OR (pefloxa*in*)
#8 MeSH descriptor Trimethoprim explode all trees
#9 (trimethoprim) OR (sulfamethoxazol*) OR (trimethoprim-sulfamethoxazol*, (trimethoprim NEAR/3 sulfamethoxazol*)) OR
(tmp-smz*)
#10 MeSH descriptor Polymyxins explode all trees
#11 (colistin) OR (nalidixic NEAR/3 acid) OR (polymyxin)
#12 MeSH descriptor Aminoglycosides explode all trees
#13 MeSH descriptor Gentamicins explode all trees
#14 MeSH descriptor Nebramycin explode all trees
#15 MeSH descriptor Neomycin explode all trees
#16 MeSH descriptor Vancomycin explode all trees
#17 (gentami*in) OR (tobramy*in) OR (meomy*in)
#18 MeSH descriptor Roxithromycin explode all trees
#19 MeSH descriptor Rifampin explode all trees
#20 (vancomy*in) OR (roxithromy*in) OR (rifampin*,rifampicin*)
#21 MeSH descriptor beta-Lactams explode all trees
#22 MeSH descriptor Penicillins explode all trees
#23 MeSH descriptor Amoxicillin explode all trees
#24 MeSH descriptor Cephalothin explode all trees
#25 MeSH descriptor Ceftriaxone explode all trees
#26 MeSH descriptor Ticarcillin explode all trees
#27 (beta-lactam*) OR (peni*illin) OR (amoxi*illin*) OR (cephalot*in*,cefalot*in*) OR (ceftriaxone*)
#28 (tica*illin*) OR (framycetin)
#29 (#1 OR #2 OR #3 OR #4 OR #5 OR #6 OR #7 OR #8 OR #9 OR #10 OR #11 OR #12 OR #13 OR #14 OR #15 OR #16
OR #17 OR #18 OR #19 OR #20 OR #21 OR #22 OR #23 OR #24 OR #25 OR #26 OR #27 OR #28)
#30 MeSH descriptor Colony-Stimulating Factors explode all trees
#31 MeSH descriptor Colony-Stimulating Factors, Recombinant explode all trees
#32 MeSH descriptor Granulocyte Colony Stimulating Factor, Recombinant explode all trees
#33 MeSH descriptor Granulocyte Colony-Stimulating Factor explode all trees
#34 MeSH descriptor Macrophage Colony-Stimulating Factor explode all trees
#35 MeSH descriptor Granulocyte-Macrophage Colony-Stimulating Factor explode all trees
#36 (rhg*csf*,rhgm*csf*) OR (rmethug*,rhmethug*) OR (rhug*,rhugm*) OR (gcsf*,g-csf*) OR (gm-csf*,gmcsf*)
#37 (granulo*yt* NEAR/3 fa*tor*) OR (ma*rophag* NEAR/5 fa*tor*) OR (csf.ti) OR (filgrastim*) OR (neupogen*)
#38 (lenograstim*) OR (euprotin*) OR (peg*filgrastim*) OR (neulasta*) OR (leukine)
#39 (molgramostine*) OR (mielogen*) OR (leucomax*) OR (granocyte)
#40 MeSH descriptor Filgrastim explode all trees
#41 (#30 OR #31 OR #32 OR #33 OR #34 OR #35 OR #36 OR #37 OR #38 OR #39 OR #40)
#42 MeSH descriptor Leukopenia, this term only
#43 .MeSH descriptor Agranulocytosis explode all trees
#44 (granulocytopen*) OR (agranulocyto*) OR (neutropen*) OR (leu*open*) OR (aplasia, aplastic, aplasion)
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#45 (leukocyt* NEAR/5 nadir) OR (neutrophil NEAR/5 nadir)
#46 MeSH descriptor Infection explode all trees
#47 (infect*)
#48 MeSH descriptor Sepsis explode all trees
#49 (septicemia, septicaemia) OR (bacteraem*, bacterem*) OR (fever*) OR (pyrexia) OR (fever NEAR/4 (unknown NEAR/3
origin))
#50 MeSH descriptor Fever explode all trees
#51 MeSH descriptor Fever of Unknown Origin, this term only
#52 (pneumonia) OR (lung inflammation) OR (pulmonary inflammation) OR (pneumonitis)
#53 (#42 OR #43 OR #44 OR #45 OR #46 OR #47 OR #48 OR #49 OR #50 OR #51 OR #52)
#54 MeSH descriptor Neoplasms by Histologic Type explode all trees
#55 MeSH descriptor Neoplasms by Site explode all trees
#56 (neoplas*) OR (krebs,cancer*) OR (malignan*)
#57 (leukaem*,leukem*) OR (lymphom*) OR (melano*) OR (metastas*) OR (mesothelio*,mesotelio*)
#58 (gliom,glioblastom*) OR (osteo*sarcom*) OR (carcinomatos*) OR (blastom*) OR (neuroblastom*)
#59 MeSH descriptor Pneumonia explode all trees
#60 (#54 OR #55 OR #56 OR #57 OR #58 OR #59)
#61 (#53 OR #59)
#62 (#29 AND #41 AND #61)
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